Key Points
- CEO Gilmore Neil O'Neill sold 5,394 shares on March 3 at an average price of $2.02 for a total of $10,895.88, trimming his holding by about 2% to 263,693 shares (valued ~ $532,660).
- Editas (NASDAQ:EDIT) was trading around $1.92 with a market cap of roughly $187.4M and a 12‑month range of $0.91–$4.54; analysts have a consensus rating of "Moderate Buy" with an average price target of $5.00.
- Editas is a clinical‑stage gene‑editing company developing CRISPR‑based therapies, including lead candidates EDIT‑101 for LCA10 and EDIT‑301 for sickle cell disease/β‑thalassemia.
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,394 shares of the firm's stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $2.02, for a total value of $10,895.88. Following the completion of the sale, the chief executive officer directly owned 263,693 shares of the company's stock, valued at approximately $532,659.86. This trade represents a 2.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Editas Medicine Stock Performance
NASDAQ:EDIT traded down $0.27 during trading hours on Thursday, hitting $1.92. 1,222,815 shares of the company's stock traded hands, compared to its average volume of 1,736,892. The firm has a market cap of $187.43 million, a P/E ratio of -0.81 and a beta of 2.16. Editas Medicine, Inc. has a twelve month low of $0.91 and a twelve month high of $4.54. The stock's fifty day moving average price is $2.01 and its two-hundred day moving average price is $2.59.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Editas Medicine in a research report on Wednesday, January 21st. Chardan Capital raised shares of Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Thursday, November 13th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Editas Medicine currently has a consensus rating of "Moderate Buy" and an average price target of $5.00.
Get Our Latest Research Report on EDIT
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of EDIT. StoneX Group Inc. acquired a new position in shares of Editas Medicine during the 4th quarter valued at about $33,000. GSA Capital Partners LLP acquired a new position in Editas Medicine during the fourth quarter valued at approximately $1,166,000. Hennion & Walsh Asset Management Inc. raised its position in shares of Editas Medicine by 15.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 279,534 shares of the company's stock valued at $573,000 after purchasing an additional 37,843 shares during the period. CIBC Bancorp USA Inc. acquired a new position in Editas Medicine during the 3rd quarter worth $57,000. Finally, Sei Investments Co. bought a new stake in Editas Medicine during the third quarter valued at about $46,000. Institutional investors own 71.90% of the company's stock.
About Editas Medicine
(
Get Free Report)
Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine's research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.
The company's pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
